Table 3.

Adjusted HRs^* and 95% CI for serum 25OHD levels with T2D, stratified by sleep behaviors

Sleep behaviors		Case subjects/N	HR (95% CI)	P for interaction
Sleep duration	Low risk	3,990/240,824	0.87 (0.86–0.89)	0.07
	High risk	2,950/109,387	0.90 (0.88–0.92)
Chronotype	Low risk	4,391/220,373	0.88 (0.86–0.89)	0.25
	High risk	2,549/129,838	0.89 (0.87–0.92)
Insomnia	Low risk	1,356/86,779	0.87 (0.84–0.90)	0.35
	High risk	5,584/263,432	0.89 (0.87–0.90)
Snoring	Low risk	3,476/221,562	0.88 (0.86–0.89)	0.27
	High risk	3,464/128,649	0.89 (0.87–0.91)
Daytime sleepiness	Low risk	6,523/341,273	0.88 (0.87–0.89)	0.0006
	High risk	417/8,938	0.92 (0.87–0.97)

^*Adjusted for age, sex, race (White European, mixed, South Asian, Black, and others), UK Biobank assessment center, average total annual household income (<£18,000, £18,000–30,999, £31,000–51,999, £52,000–100,000, >£100,000, and “do not know” or missing), Townsend deprivation index, alcohol consumption (current, former, never, or missing), smoking status (current, former, never, or missing), BMI, physical activity (MET-minutes), healthy diet score (0, 1, 2, 3, 4, and 5), sun exposure time in the summer (hours/day), season of blood collection (winter: December–February; spring: March–May; summer: June–August; and autumn: September–November), antihypertensive medications use (yes/no), cholesterol medications use (yes/no), and family history of diabetes (yes, no, and “do not know” or missing).